Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 968 across all filing types
Latest filing 2020-05-28 Regulatory Filings
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
ArcticZymes granted NOK 1.6 million funding from Innovation Norway for enzyme development project.
Regulatory Filings Classification · 100% confidence The document is a press release announcing that ArcticZymes AS has been granted NOK 1.6 million in funding from Innovation Norway for an enzyme development project related to COVID-19 diagnostic tests. This type of announcement, detailing specific corporate news, funding, or operational updates that do not fit the strict definitions of 10-K, ER, or IR, is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the funding was debt/equity related. Since this is a grant/funding announcement, CAP is a strong candidate, but RNS serves as the appropriate general regulatory announcement category for non-standard news releases that are not earnings or major corporate actions like M&A or dividends. Given the context of a specific government grant announcement, RNS is the most suitable general regulatory category for this type of news release that isn't a formal financial report or earnings release.
2020-05-28 English
ArcticZymes granted NOK 1.65 million funding from Innovation Norway for a SAN-HQ upscaling project
Capital/Financing Update Classification · 98% confidence The document is a press release announcing that the subsidiary ArcticZymes has been granted NOK 1.65 million in funding from Innovation Norway for an enzyme upscaling project. This is a specific corporate announcement regarding funding/financing activities, not a comprehensive annual report (10-K), an earnings release (ER), or a formal regulatory filing like a DIRS or MRQ. It directly relates to the company securing capital/funding for a project. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is relatively short (4172 chars) and it is a direct announcement, not an announcement *of* a larger report.
2020-05-20 English
ArcticZymes granted NOK 1.65 million funding from Innovation Norway for a SAN-HQ upscaling project
Regulatory Filings Classification · 100% confidence The document is a short press release announcing that ArcticZymes (a subsidiary of Biotec Pharmacon) received NOK 1.65 million in funding from Innovation Norway for a specific project (SAN-HQ upscaling). It contains quotes from the CEO and a representative from the funding body, and concludes with 'ENDS-'. This format is characteristic of a general corporate announcement or news release, not a formal regulatory filing like a 10-K, IR, or ER. Since it is an announcement about a specific corporate event (receiving funding/grant), and it doesn't fit the definitions for Capital/Financing Update (CAP, which usually relates to issuing securities or debt), the most appropriate general category is Regulatory Filings (RNS) as a miscellaneous corporate announcement, or potentially Capital/Financing Update (CAP) if the grant is viewed as a financing event. Given the focus is on the grant/funding announcement itself rather than a capital structure change (like issuing shares or debt), RNS serves as the best general regulatory announcement fallback, although CAP is a close second. Given the context of funding received, CAP is slightly more specific than RNS. However, looking at the definitions, CAP is for 'fundraising, financing activities, or capital structure changes'. Receiving a grant fits 'financing activities'. I will classify it as CAP.
2020-05-20 English
Biotec Pharmacon - Minutes from Annual General Meeting
AGM Information Classification · 100% confidence The document text is explicitly titled "PROTOKOLL FRA ORDINÆR GENERALFORSAMLING I BIOTEC PHARMACON ASA" (Minutes of Annual General Meeting in Biotec Pharmacon ASA) and contains detailed records of proceedings, resolutions passed (e.g., approval of annual report, election of board members, remuneration decisions), and attendance figures from a meeting held on May 14, 2020. This content perfectly matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting.
2020-05-14 English
Biotec Pharmacon - Minutes from Annual General Meeting
AGM Information Classification · 99% confidence The document explicitly states it contains the "Minutes from Annual General Meeting" and mentions the meeting was held on 14.05.2020. This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM). Although it mentions 'enclosed the minutes', the core content is the AGM material itself, making AGM-R the most specific fit over a general RPA or RNS.
2020-05-14 English
Biotec Pharmacon - Flagging av fullmakter
AGM Information Classification · 99% confidence The document text is very short (477 characters) and explicitly mentions 'Flagging av fullmakter' (Flagging of proxies/powers of attorney) and details the number of shares represented by proxies received by the Chairman for the upcoming Annual General Meeting (AGM) on May 14, 2020. This content directly relates to the administrative setup and voting rights for a general meeting, specifically concerning proxy votes received. This aligns best with the Declaration of Voting Results & Voting Rights Announcements (DVA), as it is a notification about the status of voting rights/proxies ahead of the meeting, or potentially AGM-R if it were the presentation itself, but DVA covers the mechanics of voting rights declaration. Given the focus on proxy receipt and total represented shares, DVA is the most precise fit among the options related to shareholder meetings.
2020-05-14 Norwegian

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.